TICKERNERD
Menu
ICCCICCCHealthcare · Biotechnology

ICCC Stock Forecast: ImmuCell Corp. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$11
−1.52% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 1 Aug 2026 — among the strongest tenth.

Market cap
$99.8M
Ticker Nerd rank
96 / 100
Median analyst target
—
Analysts covering
0
Total return, dividends reinvested
1W
−0.8%
1M
+7.3%
YTD
+79.5%
1Y
+84.0%
From 52W high
−5.8%
From 52W low
+142.1%
$5
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ICCC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ImmuCell Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
97
Quality
93
Volatility
92
Momentum
92
Issuance
79
Size
75
Value
72
Growth
55
Revisions
25

Accruals (97): Reported profit is backed by cash, and the company is not expanding recklessly.

Revisions (25): Analysts have, on balance, been cutting their forecasts.

The rank is the raw material. Whether the rules would actually own ImmuCell Corp. — and when they’d sell — is the membership.

Wall Street

ICCC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ICCC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4$6$8$10$12Oct 25Jan 26Apr 26Jul 26ICCC

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 July 2020Aegis CapitalInitiatesBuy$14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

ICCC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

ImmuCell Corp. (ICCC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
23.6×

Cheaper than 34% of US stocks

Price / sales
3.3×

Cheaper than 38% of US stocks

Price / book
3.4×

Cheaper than 30% of US stocks

EV / EBITDA
18.0×

Cheaper than 18% of US stocks

Growth & margins
Revenue growth (YoY)
28.4%

Higher than 79% of US stocks

Earnings growth (YoY)
34.2%

Higher than 71% of US stocks

Gross margin
45.0%

Higher than 58% of US stocks

Operating margin
19.0%

Higher than 79% of US stocks

Net margin
−1.8%

Higher than 28% of US stocks

Returns & dividend
Return on equity
−1.9%

Higher than 42% of US stocks

Return on assets
4.6%

Higher than 75% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ICCC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ICCCImmuCell Corp.$99.8M
96
PTHSPelthos Therapeutics, Inc.$99.6M
32
FBIOFortress Biotech, Inc.$104.0M
92
COYACoya Therapeutics, Inc.$98.3M
57
RANIRani Therapeutics Holdings, Inc.$105.6M
55
BDTXBlack Diamond Therapeutics, Inc.$96.8M
38
VANIVivani Medical, Inc.$108.3M
28
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ICCC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest ICCC news & analysis

ImmuCell: First Defense With Better Execution

Seeking Alpha · 24 July 2026positive

The article discusses ImmuCell's First Defense product as its core franchise with commercial momentum across year-round dairy customers. It notes improving manufacturing yields and reallocation of Re-Tain assets towards First Defense production capacity, while raising concerns about reliance on two main distributors and product concentration.

Why it matters — An ICCC watcher would care because the article highlights positive execution on First Defense, the company's primary revenue driver, while flagging ongoing risks around customer and product concentration.

FAQ

Frequently asked questions about ICCC stock

How does Ticker Nerd's model rank ICCC?

As at 1 Aug 2026, ImmuCell Corp. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (97 of 100).

What is the ICCC stock forecast for 2030?

No analyst covering ImmuCell Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ICCC are extrapolating price history, which says nothing about the business.

How has ICCC stock performed over the past year?

ImmuCell Corp. returned +84.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ImmuCell Corp. do?

ImmuCell Corporation is a biotechnology company engaged in the development, manufacture, and sale of products that improve animal health and productivity in the dairy and beef industries. The company's primary focus is on the development of products that provide alternatives to traditional antibiotics, offering innovative solutions to enhance the immune system of livestock.

What is the latest news on ICCC?

The most recent item we track (Seeking Alpha, 24 July 2026): "ImmuCell: First Defense With Better Execution". The article discusses ImmuCell's First Defense product as its core franchise with commercial momentum across year-round dairy customers. It notes improving manufacturing yields and reallocation of Re-Tain assets towards First Defense production capacity, while raising concerns about reliance on two main distributors and product concentration.

Company

About ImmuCell Corp.

ImmuCell Corporation is a biotechnology company engaged in the development, manufacture, and sale of products that improve animal health and productivity in the dairy and beef industries. The company's primary focus is on the development of products that provide alternatives to traditional antibiotics, offering innovative solutions to enhance the immune system of livestock. ImmuCell’s notable product, First Defense, helps prevent scours (diarrhea) in newborn dairy and beef calves, a common ailment that can impair growth and development and lead to high mortality rates. By addressing such pervasive health challenges in the livestock sector, ImmuCell significantly impacts agricultural productivity and sustainability. Located in the United States, ImmuCell Corporation contributes to the broader biotechnology and agricultural markets by promoting healthier livestock, thereby potentially reducing the dependency on antibiotics and aligning with global trends towards more sustainable and responsible farming practices. This focus not only underscores the company’s role in animal health innovation but also highlights its importance in food safety and the agricultural supply chain.

CEO Mr. Paul F. Olivier Te Boekhorst · 73 employees · United States · https://immucell.com